Jin-Long Chen is listed as an executive officer and director on 10 SEC Form D filings by 1 issuer between Nov 2009 and Mar 2015: NGM BIOPHARMACEUTICALS INC (South San Francisco, CA — biotechnology — 2009–2015; $106M reported sold to 28 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside David Goeddel (10 shared filings), David Schnell (10 shared filings), Peter Svennilson (10 shared filings), ARTHUR LEVINSON (8 shared filings), Helen Kim (7 shared filings) and 5 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Jin-Long. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 7 court cases matching the name, 1 bankruptcy case matching the name listed in Key records below.
What this means 8 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 10 public filings for Jin-Long Chen and found 9 differences, 2 worth asking the sponsor about: Amount sold went down between filings; Form D filed 138 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.